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Background | Recent evidence indicates that the gut microbiota is altered considerably by a variety 
of commonly prescribed medications. This study assessed the impact of two antidiabetic therapeutics 
on the gut microbiota and markers of cardiometabolic disease in metabolically dysfunctional mice.  
Materials & Methods | C57BL/6 mice were fed a high-fat diet for 24-weeks while receiving one of 
two antidiabetic therapeutics - metformin or DPP-4 inhibitor, PKF-275-055 - for the final 12 weeks. 
Mice were assessed for weight gain, glucose and cholesterol metabolism, and adiposity. In addition, 
caecal microbiota was analysed by 16S compositional sequencing and plasma metabolome was 
analysed by LC-MS/MS.  
Results | Both therapeutics had similar metabolic effects, attenuating mesenteric adiposity, improving 
cholesterol metabolism and insulin sensitivity. However, multivariate analyses of microbiota and 
metabolomics data revealed clear divergence of the therapeutic groups. While both metformin and 
PKF-275-055 mice displayed significantly decreased Firmicutes/Bacteroidetes ratios, only metformin 
harboured metabolic health-associated Akkermansia, Parabacteroides and Christensenella. 
Paradoxically, metformin also reduced α-diversity, a metric frequently associated with host metabolic 
fitness. PKF-275-055 mice displayed elevated levels of butyrate-producing Ruminococcus and 
acetogen Dorea, with reduced levels of certain plasma sphingomyelin, phosphatidylcholine and 
lysophosphatidylcholine entities. In turn, metformin reduced levels of acylcarnitines, a functional 
group associated with systemic metabolic dysfunctio. Finally, several associations were identified 
between metabolites and altered taxa. 
Conclusions | This study represents the first direct comparison of the microbiota-modifying effects of 
metformin and a DPP-4 inhibitor, and proposes several putative microbial targets both in terms of 














Current projections forecast that insulin resistance and the associated metabolic sequelae of the 
metabolic syndrome are set to become one of the greatest global threats to human health [1, 2]. While 
primary concern must be placed with upstream stemming of this epidemic, detailed exploration of 
current antidiabetic therapies is also of particular importance. We currently lack clear mechanistic 
detail for a number of such therapies, and complete comprehension may contribute to the 
development of novel targets or personalised therapeutics. One factor which has only recently 
garnered considerable attention in this regard is the gut microbiome. The adult human gastrointestinal 
tract is host to a staggering diversity of bacteria, fungi and viruses, the genetic material of which 
vastly eclipses that of our own genome [3]. Due to this same genetic and metabolic potential, the gut 
microbiome has long been suspected as implicit in human extra-intestinal health, including factors of 
metabolic regulation [4]. Relatively large-scale clini al cross-sectional observational studies have 
demonstrated a contributory role for the gut microbiome in host metabolic health. Indeed, a robust 
correlation was previously identified between increas d microbiota diversity, or gene richness, and 
host metabolic fitness [5]. Moreover, the propensity of the gut microbiota to produce metabolites such 
as branched chain amino acids has been implicated in the pathogenesis of insulin resistance in a large 
Danish cohort [6]. 
 
In addition to contributing to host health and diseas , research indicates that the gut 
microbiome often alters or is altered by certain pharmacological interventions [7]. A large study 
combining clinical datasets from two independent Belgian and Dutch studies revealed that 
medications -such as antibiotics, proton pump inhibitors, osmotic laxatives, progesterone, 
antidepressants and TNF-α inhibitors- explained the greatest degree of variance between the 
microbiota composition of faecal samples [8]. Moreov r, a recent analysis of the >2700 participant 
UKTwins Study cohort uncovered microbiome compositin associations for dozens of commonly 
prescribed oral and even topical medications [9]. Indeed, certain drugs are now recognised to be 
metabolised by gut microbiota members in reactions such as glucuronidation, reduction, oxidation and 













can further alter drug kinetics by increasing or decreasing solubility, absorption and excretion [12, 
13]. In line with this, the composition of one’s gut microbiota, which displays degrees of inter-
individual variation, may explain a degree of the variance in the personalised response observed with 
certain oral pharmaceutical therapies. One such drug which has been shown to exhibit microbiota-
mediated action is metformin. Old knowledge indicating that certain antibiotics affect metformin 
efficacy gave the first clue that the microbiota may play a role in the drugs mechanism. Preclinical 
studies identified Akkermansia muciniphila s a potential key microbe mediating the mechanistic 
effects of metformin, since the Verrucomicrobia species was consistently found to be enhanced in the 
presence of the drug [14]. This effect has also been r produced and confirmed in randomised, 
controlled and cross-sectional clinical trials [15-7]. and the corrective effects of Akkermansia 
muciniphila in models of metabolic dysfunction have previously been demonstrated in a preclinical 
setting by Everard et al. [18]. 
 
Under the current National Institute for Health and Care Excellence guidelines [19], the 
management of type-2 diabetes mellitus (T2DM) follows an order of attempted dietary-control, 
subsequently in combination with biguanide therapy (i.e.metformin), followed by combination with 
SGLT2 inhibitor, sulfonylurea, thiazolidinedione or dipeptidase peptidyl (DPP)-4 inhibitor. The first 
therapeutic assessed in this study, metformin, is one of the most widely prescribed antidiabetic drugs 
globally; while the second therapeutic, PKF-275-055, is a member of the relatively novel DPP-4 
inhibitor class of drugs. Although the effects of metformin on the microbiota have been well 
characterised, detailed metabolomics has not been applied to such studies. In addition, the microbiota-
modifying effects of DPP-4 inhibitors, and in particular PKF-275-055, is currently unknown. 
Identification and comparison of the distinct microbial signatures associated with both interventions 
(metformin and PKF-275-055) may reveal novel targets for the management of diabetes and systemic 
metabolic dysfunction. Herein, we explore and compare the effects of these functionally-distinct 















Animals, Diet & Therapies 
C57BL/6 male mice (3 weeks old; Envigo UK) were used in this diet-induced obese mouse model. 
All mice were acclimatised for 1 week in the housing facility prior to trial commencement. Animals 
were group-housed (3-4/cage) at room temperature (21°C) in a 12-h light–dark cycle (light cycle 
07:00-19:00). The study was performed in APC Microbiome Ireland, University College Cork and 
experimental procedures were carried out as per the protocols approved by the University College 
Cork Ethics Committee, with a license acquired through the Health Products Regulatory Authority. 
Mice were randomised into the three groups and maintained on a high-fat diet (Open Source Diets 
[D12492 – 60% kcal from fat; Research Diets Inc.]) ad libitum for 24 weeks, while receiving one of 
two antidiabetic therapies for the final 12 weeks. Prior to commencement of interventions, high-fat 
fed mice were compared against mice receiving normal chow for their glucose handling and insulin 
sensitivity, in order to confirm the validity of the diet-induced metabolic dysfunctional model 
(Supplementary Figure S1). At this point, high-fat diet fed mice were randomised into three groups: 
high-fat control (HFC; n 14), metformin (MET; n 14) and PKF-275-055 (PKF; n 14).  The 
interventions were delivered in the drinking water with the following doses: metformin 300 mg/kg/d 
(Sigma Aldrich Ireland) and PKF-275-055 15 mg/kg/d (Novartis Ireland). The dosage for both 
therapies were calculated and adjusted each day from the daily water intake and weekly animal body 
weights.  
 
Metabolic Test Battery 
Intraperitoneal Glucose Tolerance Test. At week 11 of intervention, mice were fasted from the start 
of light-cycle for 6 hours prior to the Intraperitoneal Glucose Tolerance Test (IPGTT). At baseline, 
duplicate blood glucose readings were recorded fromblood collected from the tail vein  (Accu-Chek 
glucometers and strips; Roche) and 1 g D-glucose/kg of bodyweight was delivered by injection into 













45, 90 and 120 min following glucose challenge. In addition, bloods were drawn at 0 and 15 min for 
quantification of plasma insulin (Mouse Insulin ELISA, Mercodia). 
 
Insulin Tolerance Test. At week 11 of intervention, mice were fasted in the same manner for the 
insulin tolerance test (ITT) as for the IPGTT. Following duplicate baseline blood glucose readings, 
intraperitoneal injection of 0.75 IU insulin/kg of bodyweight was administered. Blood glucose was 
then monitored in the same way at 15, 45, 90 and 120 min following insulin challenge. 
 
Mixed Meal Gavage. At week 11 of intervention, mice were fasted in the same manner as the 
previously described tests prior to the mixed meal gavage (MMG). Each mouse received a gastric oral 
gavage of 200 µl Ensure Plus (Abbott Nutrition, Ireland) and blood glucose readings were recorded in 
duplicate at 0, 2, 4 and 18 h post gavage. Plasma sa ples were stored and cholesterol levels were later 
quantified (EnzyChrom colorimetric assay; Cambridge Biosciences, UK). 
 
Plasma Metabolomics 
Plasma was obtained from mice at cull and frozen at -80°C prior to shipment under regularly 
replenished dry-ice to University of Alberta, Canada. The Biocrates AbsoluteIDQ p180 Kit 
(BIOCRATES Life Sciences AG, Austria) was utilised to detect and quantify ~140 metabolites within 
each plasma sample. Following initial extraction and derivatization steps, a range of specific amino 
acids, biogenic amines, acylcarnitines, lysophosphatidylcholine, phosphatidylcholines, 
sphingomyelins and hexoses present in the samples were detected and quantified on an ABI 4000 Q-
Trap mass spectrometer (MDS Sciex) run in conjunctio  with a reverse-phase HPLC-column.  
 
Compositional Microbiota Sequencing 
Microbial DNA extraction, 16S rRNA amplification and sequencing. Caecal contents were 
collected from individual mice following 12 weeks of drug intervention. Total metagenomic DNA 













where an additional bead beating step was incorporated into the protocol. Extracted DNA was 
quantified using the NanoDropTM 8000 Spectrophotometer (Thermo Fisher Scientific). Total 
genomic DNA was then subjected to PCR amplification by targeting a 464-bp fragment of the 16S 
rRNA variable region V3-V4 using the specific bacterial primer set 341F (5’- 
CCTACGGGNGGCWGCAG -3’) and 806R (5’- GACTACNVGGGTWTC AATCC -3’) with 
overhang Illumina adapters [20, 21]. Unique barcodes w re attached to the forward primer for 
facilitating the differentiation of samples. Amplicons were cleaned with the Agencourt AMPure kit 
(Beckman coulter) following the manufacturer’s instruc ions, and DNA was quantified using the 
Quant-iT PicoGreen dsDNA kit (Invitrogen). Amplicons were mixed and combined in equimolar 
ratios, and the quality and purity of the library was checked with the High Sensitivity DNA Kit 
(Agilent, Palo Alto, CA, USA) by the Bioanalyzer 2100 (Agilent). The library was sequenced on an 
Illumina MiSeq platform at CIBIO (Center of Integrative Biology) – University of Trento, Italy.   
 
Bioinformatic analysis. Sequences obtained from Illumina sequencing were processed using 
Quantitative Insights Into Microbial Ecology (QIIME) software package version 1.9 [22]. The paired-
end reads were associated to the corresponding sample through the unique barcode and joined by 
using the fastq-join method [23]. Quality filtering of Illumina data was performed as part 
of split_libraries_fastq.py, using the per-nucleotide Phred quality score (q >20), which works on a 
per-nucleotide basis, truncating reads at the position where their quality begins to drop [22, 24]. 
Uclust was then used for clustering the reads left into operational taxonomic units (OTUs) at 97% 
identity [25]. PyNAST was used to align OTUs with a minimum alignment of 150 bp and 80% of 
minimum identity, and taxonomy was assigned by using Ribosomal Database Project (RDP) classifier 
2.0.1 [26, 27] QIIME was used to generate alpha (Chao1, PD whole tree, Simpson, Shannon, 
observed OTUs) and beta diversities (Bray Curtis) di tance matrices, and principal coordinate 
analysis (PCoA) plots were generated based on the beta diversity distance matrices. Finally,  
the Galaxy Lab platform for analysing linear discriminant analysis (LDA) effect size (LEfSe) was 















All metabolic datasets were analysed by one-way analysis of variance (ANOVA) in Prism 5 
(GraphPad Software Inc.). Metabolomic data was log n rmalised prior to ANOVA, multivariate and 
correlation analyses in the MetaboAnalyst metabolomics analysis suite [29]. Sparse partial least 
square discriminant analysis (sPLS-DA) was also performed on metabolomic data [30]. For 




All animals gained significant weight over the study period (Fig. 1B; p < 0.0001). MET mice 
presented with significantly lower weights when compared to both HFC and PKF at several weekly 
timepoints throughout the study. However, both MET and HFC groups had similar weight gain at the 
end of the study. Despite this, MET mice were signif cantly lighter than PKF mice at week 24 (p < 
0.05). In addition, at sacrifice both therapeutic groups displayed a reduced quantity of mesenteric 
adipose tissue when compared to the HFC (Fig. 1C; p < 0.01). 
  
Complete MMG challenge at week 23 (i.e. week 11 of intervention period) demonstrated that 
both therapeutics improved mouse cholesterol metabolism, as both groups had returned to a 
significantly lower level of plasma cholesterol compared to the HFC group by 18 h (Fig. 1D; p < 
0.01). Although neither therapy significantly improved glucose handling during IPGTT, MET treated 
mice demonstrated a reduced level of insulin 15 min post glucose loading (Fig. 1E; p < 0.01). In 
addition, during the IPITT, MET treated mice displayed a more rapid and sustained blood glucose 
















sPLS-DA of plasma metabolomics data displays neat clus ering of MET specimen away from those of 
both HFC and PKF groups (Fig. 2A). The component metabolites of greatest importance in this sPLS-
DA plot are PC ae C34:3, C16:1, C18:1, C14, SM OH C16:1, C18:2, phenylalanine, PC aa C40:6, 
C16:2, SM OH C14:1, in order of effect (Fig. 2B). With respect to amine entities, PKF mice displayed 
increased levels of phenylalanine and reduced levels of glutamate when compared to both other 
groups (Fig. 2C; p < 0.05). Both therapeutic groups presented with reduc d threonine, while solely 
MET mice had reduced levels of methionine sulfoxide (Fig. 2C; p < 0.05). With regards 
sphingomyelins, MET mice displayed increased levels of SM OH C14:1, SM OH C16:1 and SM 
C18:0; while, conversely, PKF mice showed reduced levels of the latter two metabolites (Fig. 2D; p < 
0.05). Analysis of phosphatidylcholine metabolites d monstrated a multitude of PKF-mediated 
reductions including PC ae C34:3, PC ae C36:5, PC ae 42:3, PC aa C36:0, PC aa C40:1, PC aa 
C42:4 and lysoPC a C18:0 (Fig. 2E; p < 0.05). MET mice were found to have increased levels of PC 
ae C34:3 and decreased PC ae C42:3 (Fig. 2E; p < 0.05). Finally, the two therapeutics acted 
conversely with regards acylcarnitine entities. PKF mice displayed increased levels of 
hexadecenoylcarnatine (C16:1), octadecenoylcarnatine (C18:1) and octadecadienylcarnatine (C18:2; 
Fig. 2F; p < 0.05); while MET mice presented with reduced leve s of tetradecanoylcarnatine (C14) 
and hexadecenoylcarnatine (C16:1; Fig. 2F; p < 0.05). 
 
Microbiota Composition 
PCoA of 16S compositional sequencing data demonstrate  clear and consistent clustering of the MET 
mice microbiota as distinct from both HFC and PKF (Fig. 3A). The PCoA-related scatterplot 
demonstrates the microbial taxa most associated with each vector (Fig. 3B). The MET microbiota 
cluster most neatly associated with Mucispirillium, Bacteroides, Parabacteroides, Clostridiales, 
Christensenella and Akkermansia (Fig. 3B). Interestingly, the MET microbiota displayed reduced 
levels of several α-diversity metrics, including Shannon diversity index, when compared to both HFC 














In broad terms, LEfSe analysis revealed that the HFC microbiota was associated with 
Firmicutes, while the MET microbiota was defined by Bacteroidetes, Parabacteroides and 
Akkermansia (Fig. 4A/B). In turn, the PKF microbiota appeared to associate most closely with the 
family Ruminococcaceae and a number of low abundance taxa (Fig. 4A). With regards to phylum 
level alterations, PKF mice presented with reduced levels of Firmicutes compared to HFC (46.4 vs. 
52.4 %; p = 0.05), while MET mice displayed lower levels of the taxon compared to both other 
groups (38.7 %; p < 0.01). Conversely, the MET microbiota showed increased levels of Bacteroidetes 
compared to HFC (49.5 vs. 40.8 %; p < 0.01), and Verrucomicrobia compared to both PKF and HFC 
(3.4 vs. 0.1 and 0.01 %; p < 0.001). Both MET (p < 0.001) and PKF (p < 0.05) mice had a reduced 
Firmicutes:Bacteroidetes ratio (Fig. 4C). When compared to HFC, PKF mice displayed increased 
levels of the genera Bacteroides (19.2 vs. 11.2 %; p < 0.01), Dorea (1.0 vs. 0.2 %; p < 0.00001; Fig. 
4D) and Ruminococcus (2.0 vs. 1.2 %; p < 0.01; Fig. 3D); while displaying reduced levels of 
Odoribacter (1.5 vs. 3.5 %; p < 0.05) and Lachnoclostridium (17.4 vs. 24.2 %; p < 0.01; Fig. 3D). In 
turn, when compared to the HFC, MET mice presented with significantly increased levels of 
Bacteroides (20.6 vs. 11.2 %; p < 0.001), Akkermansia (3.4 vs. 0.02 %; p < 0.001; Fig. 4E), 
Parabacteroides (6.2 vs. 1.0 %; p < 0.001; Fig. 4F), Christensenella (0.1 vs. 0.01 %; p < 0.00001; Fig. 
4G) and Clostridiales_other (4.8 vs. 1.0 %; p < 0.00001); while displaying decreased levels of AF-12 
(0.3 vs. 0.9 %; p < 0.01), Muribaculum (10.3 vs. 14.5 %; p < 0.001), Clostridiaceae_other (0.1 vs. 0.6 
%; p < 0.0001), Lachnoclostridium (16.8 vs. 24.2 %; p < 0.01), Coprococcus (1.1 vs. 3.5 %; p < 0.05), 
Dorea (0.04 vs. 0.2 %; p < 0.00001), Papillibacter (4.6 vs. 6.4 %; p < 0.05), Oscillospira (8.0 vs. 12.5 
%; p < 0.01), Ruminococcus (0.7 vs. 1.4 %; p < 0.0001), Desulfovibrio (0.1 vs. 1.1 %; p < 0.00001) 
and Desulfovibrionaceae (0.0 vs. 0.2 %; p < 0.00001; Fig. 3D). 
 
Microbiota-Metabolite Correlation  
When conducting correlation analysis between the key taxonomic microbiota alterations observed and 
plasma metabolome, a range of positive and negative ssociations with Dorea and Christensenella 













positively correlated with several acylcarnitines (C2, C161, C182, C141, C14, C142, C162, C181 and 
C141-OH; q < 0.05) and phenylalanine (q < 0.05), and negatively correlated with a range of 
phosphatidylcholines (PC ae C343, PC aa C406, PC aa C424, PC ae C424, PC aa C361 and PC aa 
C362; q < 0.05) and a single sphingomyelin (SM OH C161; q < 0.05). Conversely, Christensenella 
relative abundance was positively correlated with phosphatidylcholines (PC ae C343, PC aa C361 PC 
aa C424, PC aa C362, PC ae C342, PC ae C365 and PC ae C321; q < 0.05) and two sphingomyelins 
(SM OH C141, SM OH C161; q < 0.05), as well as ornithi e and alanine (q < 0.05). In turn, 
Christensenella relative abundance was negatively correlated with several acylcarnitines (C14, C2, 
C161, C182, C141-OH, C142 and C162; q < 0.05), phenylalanine and kynurenine (q < 0.05). 
DISCUSSION 
The intestinal microbiome has garnered significant attention and scrutiny over the past two decades as 
an influencer of host health and disease. While we acknowledge the major impact that diet imposes on 
our gut microbiome [31], until recently, little consideration had been given to the potential impact that 
the thousands of regularly prescribed oral medications may have on this plastic enteric ecosystem. 
While metformin has been widely publicised for its microbiota-modulating and Akkermansia-
enhancing attributes, the effects of more novel classes of antidiabetic therapeutics have not been 
extensively researched. In line with this, we set out t  assess the effect of a novel DPP-4 inhibitor on 
the gut microbiota composition of metabolically dysfunctional mice. In addition, our objectives 
extended to directly compare these effects with those of metformin, in order to assess whether such 
alterations may be the result of metabolism correction, or rather if they are therapy specific. Finally, 
we examined the downstream effects of both therapeutics on several classes of potentially 
metabolically important host plasma metabolites. 
  
 Metformin remains a first-line therapeutic in the management of T2DM, acting in part 
through the suppression of hepatic gluconeogenesis and promotion of insulin sensitivity [32], while 
also contributing to a small degree of weight loss [33]. In line with this, MET mice in the present 













gain and mesenteric adiposity. The vildagliptin analogue PKF is a DPP-4 inhibitor and therefore 
confers its beneficial effects by extending the half-life of endogenous GLP-1. Consistent with this, 
PKF animals demonstrated improved cholesterol metabolism, a trend towards improved glucose 
handling and reduced mesenteric adipose tissue. These physiological changes are, for the most part, in 
line with the expected outcomes for each metabolic parameter [34-36], suggesting that the 
therapeutics functioned reasonably well in this animal model of metabolic dysfunction.  
  
Already mentioned, the administration of metformin to both animal and man has been shown 
to alter the composition of the gut microbiota with potency [17], and is rivalled in the consistency of 
these effects only by antibiotic regimes. In the current study and animal model of metabolic 
dysfunction, metformin produced many of the same eff cts which have been demonstrated previously, 
thereby reiterating this consistency. The primary identified enteric member of the Verrucomicrobia 
phylum, Akkermansia is a genus which has received a great deal of attention for its association with 
metabolic health [37]. This effect appears to be du to metformin-mediated increases in goblet cells, 
which in turn secrete mucin, a key energy source of Akkermansia [38]. The Delzenne and Cani group 
of the Catholic University of Louvain have made inroads in elucidating the putative mechanisms 
through which Akkermansia may contribute to host health in rodent models [39], focusing primarily 
on the increased levels of inflammation-attenuating e docannabinoids and promotion of the gut 
barrier integrity observed in animals exposed to the live microbe [40]. In fact, the same group has 
conducted the first ever human clinical trial involving Akkermansia as an intervention in subjects with 
obesity and metabolic dysfunction (ClinicalTrials.gov ID: NCT02637115). The results of this small-
scale phase I trial are eagerly awaited.  
 
In addition to the increased relative abundance of Akkermansia, MET mice displayed 
increases in fibre-fermenting genera P rabacteroides, a taxon which has been repeatedly associated 
with metabolic health [41-43], as well as metformin therapy, independently of metabolic status [44]. 
A recent preclinical intervention study in which obese mice were gavaged with Parabacteroides 













lumen, thereby instigating intestinal gluconeogenesis and activating farnesoid X receptor, which in 
turn improved insulin sensitivity and produced a len r phenotype [45]. Finally, the increase in 
Christensenella relative abundance following metformin intervention may be of particular interest, as 
this genera was previously associated with a lean BMI in a clinical study examining nearly 1000 
individuals from twinsets [46]. In the same study, the transfer of the obese phenotype into mice 
through microbiota transplantation from an obese donor was attenuated by the addition of a member 
of the Christensenella genus. However, it is important to note that the metformin-mediated 
augmentation of Christensenella in the present study was, albeit interindividually consistent, quite 
modest and therefore may not be clinically relevant. 
 
Curiously, metformin appeared to drastically reduce the gut microbiota α-diversity of obese 
mice, an effect which has been reported previously in rodents [47]. This result initially appears 
paradoxical in light of current knowledge, as microbiota diversity and gene richness have been found 
to associate tightly with metabolic fitness in human cohorts [5]. Although this is most likely the direct 
result of mucin production-mediated Akkermansia population inflation, it may be worth considering 
whether metformin inhibits the growth of certain microbial taxa, thereby facilitating the expansion of 
other metabolically beneficial micro-organisms. In fact, the antimicrobial attributes of metformin are 
now a topic of discussion having been demonstrated gainst several common pathogens in vitro [48, 
49] and also in a clinical context against tuberculosis infection [50-52]. In addition, metformin 
therapy is often associated with adverse gastrointest al tract symptoms, with up to a quarter of 
patients experiencing bloating, nausea or diarrhoea [53]. It may be of interest to stratify clinical 
patients on metformin monotherapy that are symptomaic and non-symptomatic of gastrointestinal 
symptoms and to examine the composition of the gut microbiota to assess whether this may be 
microbially-mediated. 
 
In this rodent model of metabolic dysfunction, DPP-4 inhibitor intervention significantly 
increased the relative abundances of D rea, Ruminococcus and Bacteroides, all of which are 













generate acetate [54], Ruminococcus pp. are known to produce acetate and butyrate, and B cteroides 
spp. contribute to the intestinal levels of both acet te and propionate [55]. Indeed, the DPP-4 inhibitor 
sitagliptin has been shown to enhance the abundances of other SCFA-producing genera, namely 
Roseburia and Blautia [56]. If these bacterial abundance increases relate to augmented SCFA 
production, then this would likely have a significant impact on metabolic function in the host. For 
example, acetate is known to participate in cholesterol synthesis pathways and lipogenesis, while also 
modulating appetite [57, 58]. In addition, propionate has been demonstrated to impact upon hepatic 
gluconeogenesis and cholesterol metabolism [59]. Finally, butyrate acts as an energy source for 
colonic enterocytes and, in turn, contributes to tight junction integrity [60]. In line with all this, a 
recent study examining the effects of vildagliptin on the rodent innate immune system and glucose 
homeostasis revealed that the caecum of these animals contained substantially greater levels of 
propionate [61], suggesting that the compositional microbiota effects translate into functional 
attributes and may contribute to the therapeutic phenotype. 
 
Metabolomics analysis of the mouse plasma revealed a mixed story in which the therapeutics 
produced substantially divergent profiles. Although both antidiabetic groups displayed reduced 
threonine levels -a free amino acid which has been shown to correlate with fasting plasma glucose in 
T2DM patients- this was the extent of their overlap with respect to amine entities [62]. Interestingly, 
glutamate was found to be depleted in the plasma of PKF mice and this metabolite was also found to 
be associated with degree of insulin resistance in the previously mentioned T2DM cohort [62]. In 
addition, metformin treated mice displayed reduced oncentrations of methionine sulfoxide, a 
proposed putative marker of oxidative stress related in diseases such as diabetes [63]. 
 
Several sphingolipids were also found to be altered following antidiabetic therapy. While 
PKF mice demonstrated decreased levels of certain sphi gomyelin species, MET appeared to have the 
counter effect. Intriguingly, while MET mice displayed increased plasma levels of several 
sphingomyelin entities, a previous PICRUSt analysis (i.e. Phylogenetic Investigation of Communities 













functional capacity) of the metformin-induced rodent microbiota displayed an increase in the levels of 
microbes associated with sphingolipid metabolism pathw ys [47]. Abundances of such entities are 
often associated with insulin resistance [64] and have been found to antagonise the activity of 
adipocyte peroxisome proliferator-activated receptor-γ in obese women [65], thereby promoting the 
diabetic phenotype [66]. Indeed, this makes the increased abundance following metformin therapy a 
curious, but interesting result. 
 
Significant attention has recently been given to microbial phosphatidylcholine metabolism 
due to the downstream cardiovascular effects of this pathway and its key metabolites trimethylamine-
N-oxide. However, the levels of circulating phosphatidylcholine entities may also offer insight into 
the metabolic state of the subject. While little alteration in phosphatidylcholine metabolism was noted 
in MET mice, those treated with the DPP-4 inhibitor displayed reduced levels of multiple metabolites 
of this class. Importantly, many closely related metabolites have been proposed as early predictive 
biomarkers of T2DM progression in humans [67, 68], due to their association with insulin resistance. 
Finally, the reduced levels of two acylcarnitines in the MET mice may also be of biological 
importance. Increased levels of these entities havebeen reported in the plasma of individuals with 
insulin insensitivity, with the running hypothesis that fatty acid oxidation rate may be reacting more 
rapidly than the tricarboxylic acid cycle in obese and metabolically dysfunctional individuals [69, 70], 
leading to the accumulation of intermediates such as acylcarnitines [71, 72].  
 
As previously eluded to, T2DM and its associated comorbidities already represent one of the 
largest contributors to morbidity and mortality in the current global population. Beyond the vastly 
augmented risk of heart disease associated with insulin resistance and the metabolic syndrome [73], 
patients and health services must persist with the downstream life-changing sequelae of the disease, 
such as distal neuropathies and retinopathies. Withthis in mind, it is of paramount importance that 
novel efficacious and tolerable therapeutics are developed to combat this life-threatening disease and 
the taxing economic ramifications which it poses. We must first gain a complete understanding of the 













therapeutic regimes. In line with this, exploration of the intestinal microbiota modifying effects may 
be of central importance. Finally, as diabetic management is often not straightforward, increasing 
numbers of patients are receiving multiple or combination oral therapeutics, such as a combined 
sitagliptin-metformin formulation. The interactive effects of such medications should be considered in 
future preclinical and clinical studies, in order to understand the ramifications to the gut microbiota. 
 
Herein we have explored for the first time the microbiota and metabolome effects of a novel 
DPP-4 inhibitor, PKF-275-055, and compared them directly against the well-characterized biguanide, 
metformin. The data presented indicates that, while metformin had a greater overall effect on the 
composition of the intestinal microbiota, the subtler alterations observed in the PKF treated mice may 
indeed be of biological significance due to the metabolic capabilities of the taxa involved. Future 
directions should include the isolation and application of these potentially metabolically important 
microbes to models of metabolic disease. In addition, the microbiota of clinical patients on metformin 
monotherapy should be examined and stratified by their gastrointestinal symptoms in order to explore 
any potential role of this microbial ecosystem in the variability of this phenotype. Finally, we have 
identified specific plasma metabolites which may be of importance to the therapeutic course of these 
antidiabetic compounds, either as markers or disease modifying compounds, and explored the 
associations of these metabolites with altered taxa. In conclusion, the intestinal microbiota 
composition of metabolically dysfunctional mice is altered in a treatment-specific manner, which may 
point to a role of the gut microbiota in their mechanisms of action. 
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Figure 1 | Study Design, Body Profiling and Metabolic Assessment Following Antidiabetic 
Therapy. (A) Mouse trial design and procedures detailed above, with high-fat diet represented by 
yellow bar and intervention by broken grey bar. (B) Delta change in body weights over the pre-
feeding (white background) and intervention (red background) periods for HFC [red; n = 13], PFK 
[blue; n = 14] and MET [green; n = 14]. Tall dark red boxes represent metabolic test weeks 
(GTT/ITT and MMG, respectively). (C) Epididymal (EAT), subcutaneous (SAT) and mesenteric 
adipose tissue (MAT), as well as liver tissue weights are depicted. (D) Post-prandial serum 
cholesterol levels during the 18 hours following MMG. (E) Serum glucose (lines) and insulin (bars) 
levels during GTT. (F) Serum glucose levels during ITT. Data was analysed by one-way ANOVA with 
Bonferroni correction. Significant differences betwen groups are represented as follows: HFC-MET 
*(p < 0.05), **(p < 0.01), ***(p < 0.001), ****(p <  0.0001); HFC-PFK $(p < 0.05), $$(p < 0.01), 
$$$(p < 0.001), $$$$(p < 0.0001); MET-PFK #(p < 0.05), ##(p < 0.01), ###(p < 0.001), ####(p < 0.0001). 
Plots depict replicates with mean and SEM. 
 
Figure 2 | Plasma Metabolomics Reveals Contrasting Effects of Metformin and DPP-4 Inhibitor 
Therapy. (A) Partial least squares discriminant analysis plot displays PFK [blue], MET [green] and 
HFC [red] samples. (B) Plot loadings graph demonstrating the variables of importance to the partial 
least squares discriminant analysis and the group with hich each variable is positively (green box) 
or negatively (red box) related. Quantitative data is displayed for the metabolites which were 
significantly altered by PFK or MET; these includes amino acids and biogenic amines (C), 
sphingolipids (D), diacyl-phosphatidylcholine (PC aa) and acyl-alkyl-phosphatidylcholine (PC ae; E) 
and acylcarnitines (F). Data was analysed by one-way ANOVA and a false discovery rate was 
applied. Significant differences between groups are represented as follows: HFC-MET *(q < 0.05), 
**(q < 0.01), ***(q < 0.001), ****(q < 0.0001); HFC-PFK $(q < 0.05), $$(q < 0.01), $$$(q < 0.001), 
$$$$(q < 0.0001); MET-PFK #(q < 0.05), ##(q < 0.01), ###(q < 0.001), ####(q < 0.0001). Plots depict 














Figure 3 | Gut Microbiota Composition is Substantially Altered by Metformin and, to a Lesser 
Extent, DPP-4 Inhibitor Therapy. (A) Principle coordinate analysis (PCoA) of compositional 
sequencing data. (B) Scatterplot associated with PCoA plot. (C) Shannon diversity index of 
microbiota sequencing data. (D) Genera relative abundances of each sample displayed in horizontal 
and divided into PFK [blue], MET [green] and HFC [red]. Data was analysed by one-way ANOVA 
with a Bonferroni correction. Significant differences between groups are represented as follows: 
HFC-MET ****(p < 0.0001); MET-PFK ###(p < 0.001). Plots depict replicates with mean and SEM.  
 
Figure 4 | Both Metformin and DPP-4 Inhibitor Therapy Associate with Unique Taxonomic 
Markers and Enhance the Relative Abundances of Potentially Metabolically Important 
Microbes. Linear discriminant analysis (LDA) effect size (LEfSe) (A) barchat and (B) cladogram 
representation of taxa associated with HFC and antidiabetic therapies. (C) Ratio of relative 
abundances of Firmicutes to Bacteroidetes. (D) Relative abundances of the genus Dorea. (E) Relative 
abundances of the genus Akkermansia. (F) Relative abundances of the genus Parabacteroides. (G) 
Relative abundances of the genus Christensenella. PFK [blue], MET [green] and HFC [red]. 
Significant differences between groups are represent d as follows: HFC-MET *(q < 0.05), **(q < 
0.01), ***(q < 0.001), ****(q < 0.0001); HFC-PFK $(q < 0.05), $$(q < 0.01), $$$(q < 0.001), $$$$(q < 
0.0001); MET-PFK #(q < 0.05), ##(q < 0.01), ###(q < 0.001), ####(q < 0.0001). Plots depict replicates 

































































Figure S1. Glucose and Insulin Tolerance Tests for Confirmation of Metabolic Dysfunction in Diet 
Induced Obesity Model. At week 12, prior to commencement of antidiabetic interventions, high-fat diet 
fed animals (HFC) were assessed against animals receiving only normal chow (NC) for their glucose 
handling by intraperitoneal glucose tolerance test [A/B] and by insulin tolerance test [C/D]. In addition, 
mouse weight was monitored over the initial 12 weeks to demonstrate and validate the diet-induced 
















Figure S2. Correlation Analysis Between Key Taxonomic Alterations and Plasma Metabolomics. 
Pearson correlation analysis was carried out between key taxonomic alterations highlighted in Figure 4 
and plasma metabolomics data for each animal. The above plots depict the top 25 compounds 
correlated with [A] Dorea, [B] Akkermansia, [C] Parabacteroides and [D] Christensenella genera relative 
abundances, with the correlation co-efficient displayed on the x-axis. Statistically significant interactions 
are annotated with *, which indicates an FDR q value of < 0.05. 
